#	Pagina
attuale pagina	/open-h2020/projects/207225/index.html
-1	/open-h2020/projects/210859/index.html
-2	/open-h2020/projects/223179/index.html

Opendata, web and dolomites

OptiMalVax SIGNED

Optimizing a deployable high efficacy malaria vaccine

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

OptiMalVax project word cloud

Explore the words cloud of the OptiMalVax project. It provides you a very rough idea of what is the project "OptiMalVax" about.

accelerated molecules infectious candidates antigen biotech malaria parasites timeline subunit vaccines attaining bonding harmonise malariologists vaccine immune characterised multiple criteria companies durability constructed position virus australia assays immunogenicity science excellent posed stringent advantage functional immunisation africa peptides release vectors roadmaps eluted falciparum toughest microcapsules chance vaccinology technologies edctp clinical magnitude usa liver feasible chances particles collaborate delayed optimising deaths global developers million discovery polymorphic prevent sequencing rapid transgenes half fit tackling antigens efficacy foremost tackles linked avoiding health hla link helping plasmodium pharma expressing groups stage progression commercial

Project "OptiMalVax" data sheet

The following table provides information about the project.

Coordinator	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.optimalvax.eu
Total cost	23˙701˙228 €
EC max contribution	20˙050˙441 € (85%)
Programme	1. H2020-EU.3.1.2. (Preventing disease)
Code Call	H2020-SC1-2016-RTD
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2021-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	coordinator	13˙051˙666.00
2	STICHTING KATHOLIEKE UNIVERSITEIT STICHTING KATHOLIEKE UNIVERSITEIT Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ website: www.radboudumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	participant	4˙427˙500.00
3	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	1˙175˙000.00
4	SORBONNE UNIVERSITE SORBONNE UNIVERSITE Organization address address: 21 RUE DE L'ECOLE DE MEDECINE city: PARIS postcode: 75006 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	437˙500.00
5	GENOME RESEARCH LIMITED GENOME RESEARCH LIMITED Organization address address: THE GIBBS BUILDING, EUSTON ROAD 215 city: LONDON postcode: NW1 2BE website: http://www.sanger.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	250˙000.00
6	STATENS SERUM INSTITUT STATENS SERUM INSTITUT Organization address address: ARTILLERIVEJ 5 city: KOBENHAVN S postcode: 2300 website: www.ssi.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (KOBENHAVN S)	participant	250˙000.00
7	INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT Organization address address: BOULEVARD DE DUNKERQUE 44 CS 90009 city: MARSEILLE postcode: 13572 website: www.ird.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (MARSEILLE)	participant	183˙775.00
8	NOVAVAX AB NOVAVAX AB Organization address address: KUNGSGATAN 109 city: UPPSALA postcode: 753 18 website: www.isconova.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	participant	150˙000.00
9	EXPRES2ION BIOTECHNOLOGIES APS EXPRES2ION BIOTECHNOLOGIES APS Organization address address: AGERN ALLE 1 city: HORSHOLM postcode: 2970 website: www.expres2ionbio.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (HORSHOLM)	participant	25˙000.00
10	JANSSEN VACCINES & PREVENTION BV JANSSEN VACCINES & PREVENTION BV Organization address address: ARCHIMEDESWEG 4 city: LEIDEN postcode: 2333 CN website: www.crucell.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	25˙000.00
11	PROGRAM FOR APPROPRIATE TECHNOLOGYIN HEALTH PROGRAM FOR APPROPRIATE TECHNOLOGYIN HEALTH Organization address address: Leary WAY NW 1455 city: Seattle WA postcode: 98107-5136 website: www.path.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (Seattle WA)	participant	25˙000.00
12	UNITED KINGDOM RESEARCH AND INNOVATION UNITED KINGDOM RESEARCH AND INNOVATION Organization address address: POLARIS HOUSE NORTH STAR AVENUE city: SWINDON postcode: SN2 1FL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (SWINDON)	participant	25˙000.00
13	OSIVAX SAS OSIVAX SAS Organization address address: 4 RUE DE COPENHAGUE city: PARIS postcode: 75008 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	19˙841.00
14	IMAXIO SA IMAXIO SA Organization address address: RUE SAINT ROCH 5/7 city: PARIS postcode: 75001 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	5˙158.00
15	JAMES COOK UNIVERSITY JAMES COOK UNIVERSITY Organization address address: JAMES COOK UNIVERSITY city: TOWNSVILLE postcode: 4811 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AU (TOWNSVILLE)	participant	0.00
16	MEDICAL RESEARCH COUNCIL MEDICAL RESEARCH COUNCIL Organization address address: NORTH STAR AVENUE POLARIS HOUSE 2 FLOOR DAVID PHILLIPS BUILDING city: SWINDON postcode: SN2 1FL website: www.mrc.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (SWINDON)	participant	0.00
17	UNIVERSITE DE LAUSANNE UNIVERSITE DE LAUSANNE Organization address address: Quartier Unil-Centre Bâtiment Unicentre city: LAUSANNE postcode: 1015 website: www.unil.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (LAUSANNE)	participant	0.00
18	UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 Organization address address: Place Jussieu 4 city: PARIS postcode: 75252 website: www.upmc.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	0.00

Map

Project objective

A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates. Our approach tackles the toughest problems in malaria vaccine design: choice of the best antigens, attaining high immunogenicity, avoiding polymorphic antigens and increasing the durability of vaccine immunogenicity and efficacy. We take advantage of several recent advances in vaccinology and adopt some very new technologies: sequencing malaria peptides eluted from the HLA molecules, parasites expressing multiple transgenes, multi-antigen virus-like particles constructed with new bonding technologies, delayed release microcapsules, and liver-targeted immunisation with vaccine vectors. We enhance our chances of success by using a multi-stage multi-antigen approach, by optimising the magnitude and durability of well-characterised immune responses to key antigens, and using stringent infectious challenges and functional assays as established criteria for progression at each stage. The consortium comprises many of the foremost researchers in this field in Europe with leading groups in the USA, Australia and Africa. We link to EDCTP programmes and harmonise our timeline to fit with the recent roadmaps for malaria vaccine development. We include a major pharma partner and several excellent European biotech companies helping enhance Europe’s leading position in the commercial development of vaccines. This ambitious and exciting programme should have a high chance of success in tackling the major global health problem posed by malaria.

Deliverables

List of deliverables.
10.1 Creation of website	Websites, patent fillings, videos etc.	2020-02-17 15:51:23
10.2 Establish relevant committees including PSC, PMMC, ISAC	Documents, reports	2020-02-17 15:51:23
4.4 Generate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPs	Documents, reports	2020-02-17 15:51:23

Take a look to the deliverables list in detail: detailed list of OptiMalVax deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Roos M. Jong, Surafel K. Tebeje, Lisette Meersteinâ€Kessel, Fitsum G. Tadesse, Matthijs M. Jore, Will Stone, Teun Bousema Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites published pages: 190-215, ISSN: 0105-2896, DOI: 10.1111/imr.12828	Immunological Reviews 293/1	2020-03-05
2020	Paulo Bettencourt Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens published pages: Article 190, ISSN: 1664-3224, DOI: 10.3389/fimmu.2020.00190	Frontiers in Immunology 11	2020-03-05
2019	Susheel K. Singh, Susan Thrane, Bishwanath K. Chourasia, Karina Teelen, Wouter Graumans, Rianne Stoter, Geert-Jan van Gemert, Marga G. van de Vegte-Bolmer, Morten A. Nielsen, Ali Salanti, Adam F. Sander, Robert W. Sauerwein, Matthijs M. Jore, Michael Theisen Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum published pages: Article 1256, ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.01256	Frontiers in Immunology 10	2020-03-05
2019	Joseph J. Illingworth, Daniel G. Alanine, Rebecca Brown, Jennifer M. Marshall, Helen E. Bartlett, Sarah E. Silk, GeneviÃ¨ve M. LabbÃ©, Doris Quinkert, Jee Sun Cho, Jason P. Wendler, David J. Pattinson, Lea Barfod, Alexander D. Douglas, Michael W. Shea, Katherine E. Wright, Simone C. de Cassan, Matthew K. Higgins, Simon J. Draper Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens published pages: Article 1254, ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.01254	Frontiers in Immunology 10	2020-03-05
2019	Daniel G.W. Alanine, Doris Quinkert, Rasika Kumarasingha, Shahid Mehmood, Francesca R. Donnellan, Nana K. Minkah, Bernadeta Dadonaite, Ababacar Diouf, Francis Galaway, Sarah E. Silk, Abhishek Jamwal, Jennifer M. Marshall, Kazutoyo Miura, Lander Foquet, Sean C. Elias, GeneviÃ¨ve M. LabbÃ©, Alexander D. Douglas, Jing Jin, Ruth O. Payne, Joseph J. Illingworth, David J. Pattinson, David Pulido, Barnab Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies published pages: 216-228.e21, ISSN: 0092-8674, DOI: 10.1016/j.cell.2019.05.025	Cell 178/1	2020-03-05
2019	Arianna Marini, Yu Zhou, Yuanyuan Li, Iona J. Taylor, Darren B. Leneghan, Jing Jin, Marija Zaric, David Mekhaiel, Carole A. Long, Kazutoyo Miura, Sumi Biswas A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response published pages: Artiicle 2931, ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.02931	Frontiers in Immunology 10	2020-03-05
2018	Kirsten Dundas, Melanie J. Shears, Yi Sun, Christine S. Hopp, Cecile Crosnier, Tom Metcalf, Gareth Girling, Photini Sinnis, Oliver Billker, Gavin J. Wright Alpha-vâ€“containing integrins are host receptors for the Plasmodium falciparum sporozoite surface protein, TRAP published pages: 4477-4482, ISSN: 0027-8424, DOI: 10.1073/pnas.1719660115	Proceedings of the National Academy of Sciences 115/17	2020-02-17

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTIMALVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTIMALVAX" are provided by the European Opendata Portal: CORDIS opendata.